JP2012502649A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502649A5
JP2012502649A5 JP2011527406A JP2011527406A JP2012502649A5 JP 2012502649 A5 JP2012502649 A5 JP 2012502649A5 JP 2011527406 A JP2011527406 A JP 2011527406A JP 2011527406 A JP2011527406 A JP 2011527406A JP 2012502649 A5 JP2012502649 A5 JP 2012502649A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011527406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502649A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2009/051216 external-priority patent/WO2010032059A2/en
Publication of JP2012502649A publication Critical patent/JP2012502649A/ja
Publication of JP2012502649A5 publication Critical patent/JP2012502649A5/ja
Withdrawn legal-status Critical Current

Links

JP2011527406A 2008-09-19 2009-09-18 Cd105を対象とする標的結合剤およびその使用 Withdrawn JP2012502649A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9868508P 2008-09-19 2008-09-19
US61/098,685 2008-09-19
PCT/GB2009/051216 WO2010032059A2 (en) 2008-09-19 2009-09-18 Targeted binding agents directed to cd105 and uses thereof

Publications (2)

Publication Number Publication Date
JP2012502649A JP2012502649A (ja) 2012-02-02
JP2012502649A5 true JP2012502649A5 (enExample) 2012-11-01

Family

ID=41263674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011527406A Withdrawn JP2012502649A (ja) 2008-09-19 2009-09-18 Cd105を対象とする標的結合剤およびその使用

Country Status (9)

Country Link
US (1) US20100196398A1 (enExample)
EP (1) EP2344541A2 (enExample)
JP (1) JP2012502649A (enExample)
KR (1) KR20110057245A (enExample)
CN (1) CN102388067A (enExample)
AU (1) AU2009294414A1 (enExample)
BR (1) BRPI0918555A2 (enExample)
CA (1) CA2737667A1 (enExample)
WO (1) WO2010032059A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010151A2 (en) 2003-06-27 2005-02-03 Abgenix, Inc Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
ES2378407T3 (es) 2006-09-01 2012-04-12 Therapeutic Human Polyclonals, Inc. Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP2949666B1 (en) 2008-12-19 2018-12-19 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
EP2556172A4 (en) 2010-04-06 2013-10-30 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASES
EP2632951B1 (en) * 2010-10-27 2017-08-02 Amgen Inc. Dkk1 antibodies and methods of use
JP2014508523A (ja) * 2011-02-23 2014-04-10 ヘルス リサーチ インコーポレイテッド 抗エンドグリン抗体及び新規ヒト/マウスキメラエンドグリンを発現するノックインマウス
MX2013010011A (es) * 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
LT2723379T (lt) 2011-06-23 2018-10-25 Biogen International Neuroscience Gmbh Anti-alfa sinukleiną rišančios molekulės
US20130156766A1 (en) * 2011-11-15 2013-06-20 Allergan, Inc. Treatment of dry age related macular degeneration
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
CN113862300A (zh) * 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
CN106928359B (zh) * 2015-12-30 2020-10-13 广西医科大学 一种CD105纳米抗体Nb59
CN106928355B (zh) * 2015-12-30 2020-09-29 广西医科大学 一种CD105纳米抗体Nb184
ES2970828T3 (es) 2016-02-10 2024-05-30 Univ Rutgers Nuevos anticuerpos anti-lam
JP7092684B2 (ja) * 2016-06-14 2022-06-28 シーダーズ-サイナイ メディカル センター エンドグリン拮抗作用による治療に対する、腫瘍の感受性化法
LT3672631T (lt) 2017-08-22 2023-04-25 Biogen Ma Inc. Farmacinės kompozicijos, kurių sudėtyje yra antikūnų prieš beta amiloidą
CN108912212B (zh) * 2018-06-28 2019-08-30 中山大学附属口腔医院 一种与cd105特异性结合的多肽及其应用
WO2020106461A2 (en) * 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2021207433A2 (en) * 2020-04-07 2021-10-14 The Regents Of The University Of California Epitopes of sars-cov-2 neutralizing antibodies
CN112426526B (zh) * 2021-01-25 2021-04-06 北京达熙生物科技有限公司 一种nk细胞的制备方法及其在治疗癌症中的应用
CN112876538B (zh) * 2021-02-04 2022-09-30 福建医科大学 靶向新生血管标记物cd105的多肽及其应用
WO2022187710A1 (en) * 2021-03-05 2022-09-09 Atreca, Inc. Epha2 antibodies
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250154264A1 (en) * 2022-01-24 2025-05-15 Genovac Antibody Discovery Llc Anti-alk1 antibodies and methods of using the same
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025045032A1 (zh) * 2023-08-29 2025-03-06 应世生物科技(南京)有限公司 一种靶向cd105的抗体或其抗原结合片段及其应用
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
KR20250174161A (ko) * 2024-06-04 2025-12-12 한국과학기술연구원 엔도글린 및 메소테린 이중 항원 표적 car 및 이의 용도
TWI882851B (zh) * 2024-06-27 2025-05-01 蔡政育 基於專利技術元素整合之專利分析系統及其方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190660B1 (en) * 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
EP2281843B1 (en) * 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS

Similar Documents

Publication Publication Date Title
JP2012502649A5 (enExample)
JP2012525829A5 (enExample)
WO2010095031A3 (en) Humanized antibodies that bind to cd19 and their uses
JP2013198490A5 (enExample)
JP2014526898A5 (enExample)
JP2016512551A5 (enExample)
JP2014534242A5 (enExample)
JP2013538057A5 (enExample)
JP2011526480A5 (enExample)
JP2015504421A5 (enExample)
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
JP2017052784A5 (enExample)
JP2020504101A5 (enExample)
JP2013544756A5 (enExample)
JP2009225799A5 (enExample)
JP2015504306A5 (enExample)
RU2020129387A (ru) Антитела к pd-1 собак
RU2017128882A (ru) Антитела к биотину и способы их применения
JP2013517330A5 (enExample)
JP2013545455A5 (enExample)
JP2010515717A5 (enExample)
JP2011517447A5 (enExample)
RU2012142230A (ru) Антитела против csf-1r человека и их применение
JP2012531922A5 (ja) Toll様受容体2へのヒト化抗体またはその抗原結合部位
RU2012142231A (ru) Антитела против csf-1r человека и их применение